Tuesday, September 18, 2012
Jennerex Inc., of San Francisco, presented Phase II data on JX-594, its engineered oncolytic immunotherapy, delivered first intravenously and then through intra-tumoral route, demonstrating safety, disease control and tumor response in hepatocellular carcinoma (HCC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.